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Executive Summary
•  Every year, Forward empowers over 10,000 prisoners with drug and alcohol problems to 
break the cycle of crime and addiction and to achieve transformational change – from initial 
advice, harm minimisation and clinical treatment, to intensive programmes that instil and sustain 
recovery, and access to networks of support upon release to the community.
• Drug-related deaths in England and Wales are at record levels: 3,756 deaths in 2017/18, of 
which 53% involved an opioid (e.g. heroin) overdose. Death rates among prisoners (especially 
those on post-release supervision) are many times higher than in the general population. There 
were 955 deaths of offenders in the community in England and Wales in 2017/18. The few 
weeks immediately after release from prison is a particularly high-risk period for drug-related 
death.
• In response to these findings, and as part of our commitment to continually improve services and to deliver the best care possible, 
Forward have instigated a highly-targeted initiative to increase the number of service users being released from prison with Take Home 
Naloxone (THN), a drug that can save lives by reversing the reduced breathing rate caused by an opioid overdose.
• First piloted at HMP Lewes in 2018, and since implemented in 10 other prisons, Forward’s initiative has centred on nominating a 
dedicated practitioner as ‘Naloxone Lead’ to take responsibility for training prison leavers on how to use the drug (administered by 
injection) and for providing THN kits upon their release. 
• As a result of this initiative, National Drug Treatment Monitoring System statistics show that 42% of opioid service users across these 11 
prisons have been released with THN, more than three times the national average of 12%, with many lives saved as a consequence. 
• Building on these impressive results, Forward aims to further improve take-up rates of THN in prisons where it has already been 
introduced and to promote the initiative in all other prisons where we operate. As part of these plans, and in line with our ethos of service 
user empowerment, we will upskill peer supporters so they can train service users on how to use THN. 
Take Home Naloxone: best practice in 
preventing fatal opioid overdoses for 
prison leavers
Pulse is a series of briefings from The Forward Trust for staff, partners, commissioners and stakeholders to communicate:
• Insight from our research team’s analysis of client data and other findings 
• Examples of innovation and continuous service improvement 
• Evidence of our personal, social and economic impact
We also aim for these briefings to contribute to wider policy and practice debates.
The Forward Trust (Forward) provide a range of care, support and employment services to people struggling with drug or alcohol 
dependence or who have a history of offending. Despite our clients being amongst the most marginalised in society, we believe in 
everyone’s ability to transform their lives and to achieve recovery from a lifestyle of addiction and crime.
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The number of drug-related deaths in England and Wales is at an all-time high, with 3,756 deaths in 2017. 53% of these 
deaths involved an opioid.1
Deaths involving fentanyl – a synthetic opioid that is 50 times more potent than heroin – rose by 29% in 2017.2 
There does not currently appear to be widespread demand for fentanyl-laced heroin in the UK3 and it is hard 
to tell from sight alone whether a batch of heroin contains fentanyl. This suggests that heroin users may be 
consuming fentanyl unknowingly.
People leaving prison are at the highest risk of overdose and drug-related death in the first weeks following 
release.4, 5 This is likely due to reduced tolerance to heroin, increased purity of drugs compared to those used in 
prison6 and the tendency of some released prisoners to return to previous drug use patterns.
Increasing the uptake of Take Home Naloxone (THN) amongst opioid users leaving prison (and in the community) 
can help reduce the number of drug-related deaths7 amongst this high risk population.
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What is Take Home Naloxone (THN)?
THN is a prescription-only drug that can reverse the effects of opioids such as heroin, morphine, buprenorphine, 
codeine, methadone, opium, pethidine and fentanyl. It does not affect non-opioid drugs such as crack cocaine, ecstasy 
and cannabis (among others). THN can reverse the reduced breathing rate caused by an opioid overdose and therefore 
prevent death.8
THN is supplied in a kit that includes a syringe pre-filled with naloxone and needles. Once 
a needle has been twisted onto the syringe, it can be injected into the muscle. It takes 
approximately 2-5 minutes for naloxone to have an effect which lasts for 20-30 minutes. 
More than one dose can be given if someone returns to an overdose state after the effects 
have worn off.9
Since October 2015, drug services in prisons and the community can supply THN to service 
users without a prescription. Pharmacists who provide services such as needle exchange 
programmes can also supply THN. This means that any opioid users at risk of overdose, as 
well as their family, friends and peers, can obtain naloxone to save a life in an emergency.10
National policy and practice recommendations 
Public Health England have published guidance on the amount of THN that each local authority should make available 
to prevent opioid overdose deaths. The suggested quantity of THN supplied is based on each local authority providing 20 
times the number of THN kits as there are drug-related deaths in the area. As a minimum, every opioid user in contact with 
treatment services should be provided with THN, with extra supplies available for those not accessing treatment, e.g. those 
living in hostels.11
In January 2011, Scotland became the first country to implement a funded and evaluated National Naloxone Policy (NNP). 
In 2006-2010, there were 1,970 opioid-related deaths amongst ex-prisoners in Scotland – 9.8% of these were within the 
first four weeks of release. In the first three years (2011-2013) of Scotland’s NNP, 2,273 THN kits were given to opioid users 
leaving prison, 5.9 times the national rate of opioid-related deaths. During this time, there were 1,212 opioid-related deaths, of 
which 6.3% were in the first four weeks of release. The introduction of a NNP was therefore associated with a 36% reduction 
in opioid-related deaths in the first four weeks of release from prison.12
In 2017/18, only 51% of prisons in England had a THN programme and only 12% of opioid service users were released with 
THN.13
Rise in drug-related death
1,970 opioid-
related deaths in 
Scotland between 
2006-10
Scottish national naloxone 
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Our approach
Every year, Forward supports over 10,000 prisoners with drug and alcohol problems to break the cycle of crime and addiction 
and to achieve transformational change. Our Theory of Change framework (illustrated below) outlines how we give our service 
users the care and inspiration to believe that a different way of life is possible. Although every individual’s journey is different and 
not always smooth or linear, our drug and alcohol recovery services start with keeping people safe, whilst increasing motivation 
to change, building skills for recovery and increasing engagement with support networks. We work with service users in this way 
to help them achieve their recovery goals and live positive lives, free from crime and addiction.
Recommendations have been made by the Advisory Council on the Misuse of Drugs to improve coverage but the reasons for 
prisons not having a THN programme include prisoners mainly being transferred to other establishments rather than released 
directly back into the community, or high churn of people entering and leaving prison. Foreign national prisoners or those 
subject to immigration control are not given THN as the legal status of naloxone varies internationally.14
Where THN programmes are available in prison, there are a number of factors contributing to low take-up by opioid users 
leaving prison.15 Service providers in prisons with a high number of individuals on remand or with a high churn have a limited 
window of opportunity to offer THN. Opioid service users who are not receiving opioid substitution therapy are less likely to 
be offered THN, perhaps due to providers focusing THN distribution on those they believe to be at highest risk of overdose 
upon release. Finally, service users may be offered THN, but refuse it because they believe they will not use opioids again and 
therefore think they have no need for it.
Pause Engage Develop Prosper
Assessment and 
stabilisation of drug 
use, immediate medical 
care and prescribing
Working on motivation 
to change, and skills for 
recovery
Working through our 
structured 12 step 
recovery programmes, 
engagement with 
support networks
Independent and 
positive lifestyle, free of 
crime and addiction
 • Harm reduction 
advice and services
 •   Initial assessment 
and medical care
 •   Information and 
guidance workshops
•   Peer-led motivational 
workshops
•   Substitution 
treatment
•    Individual recovery 
planning
•   Short motivational 
programmes (e.g. 
Stepping Stones)
•   Intensive structured 
12 step programmes
• Structured one-to-
one counselling
• Peer support 
and mutual aid 
programmes
• Recovery support
• Employment and 
housing offers
• Recovery networks 
and communities
Within this framework, we offer THN as a ‘pause’ intervention to opioid users as part of our range of harm reduction services.  
It is especially important for those on remand or short sentences with whom we do not have much time to work before they 
are released into the community. However, even in these instances, training service users on using THN and having discussions 
with them about overdose can instigate the process of change in their drug-using behaviour, making them stop and think, 
and motivating them to take the first few steps on their recovery journey. THN is also important for those further advanced in 
recovery (who have reached ‘Develop’ in our Theory of Change) in case of relapse upon release or to enable them to help others 
who might overdose in the community. 
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Maximising take-up of THN
Forward have developed the following best practice process to increase the number of service users accepting THN ahead of their 
return to the community:
1. Assign a Naloxone Lead in each service
The Naloxone Lead (a clinical practitioner) is responsible for monitoring and coordinating all aspects of THN training and 
provision. They ensure all staff are trained and up to date with local processes.
                                       
2. Add all new receptions to the naloxone waiting list, regardless of release date
Every new opioid service user is added to the naloxone waiting list as soon as they engage with us in each prison. Service users 
who are due for release are booked in for a THN appointment in the two weeks before they leave prison. This appointment is also 
an opportunity to give wider release advice and information.
  
3. If a service user declines THN, we offer again at another time
Sometimes service users refuse the naloxone or the training when it is first offered, for different reasons. When this happens, we 
give service users other opportunities to engage and to undertake the training. Context and timing is important in how the drug is 
presented; all members of staff are confident and ready to speak to service users about naloxone, when the moment is right, to 
encourage uptake. 
  
4. Provide THN training in group sessions
Forward’s Living Safely programme (a series of workshops providing safe coping skills to minimise risk of harm and relapse) 
includes a session on reducing the risk of overdose. Our clinical practitioners attend this session to provide group training on 
naloxone. Training needles are used to show service users how to open the THN pack and assemble the needle. Everyone in the 
group has a chance to practice this.
5. Re-offer and reminders on the day of release
If a service user has previously refused training, a nurse takes a THN kit to reception on their release date, re-offers training and 
provides the kit if the service user changes their mind and accepts. If a service user has already accepted THN, information and 
advice is provided again on the day of release.
6. Accurate recording and good communication skills
Good communication between Forward team members and other departments in each prison ensures that we gain release dates 
for our service users in a timely manner. Without accurate recording of release dates and training completion, we would not be 
able to provide THN and training to many of our service users before they are released.
Impact
The comprehensive approach to THN described above was first implemented by Forward in HMP Lewes in 2018. Within a year of 
implementing the initiative, the number of opioid service users at HMP Lewes who were released with a naloxone kit was at 48%, 
4 times higher than the national average. Following an unannounced inspection of HMP Lewes in January 2019, Her Majesty’s 
Inspectorate of Prisons praised our approach to THN and how it contributed to good discharge planning 
for prisoners. 
42%
of opioid service users 
across 11 prisons now take 
Naloxone home and help to 
save lives in the community, 
as part of Forward's new 
initiative
*These are prisons where we provide clinical treatment and where we have qualified nurses to deliver THN training and provide 
kits; we have not yet implemented the approach in the 8 prisons where we only delivery psychosocial interventions and where the 
clinical service is delivered by a partner organisation.
The approach was then implemented across our services in Kent and Surrey prisons*. The table on the 
next page sets outs the impact of this approach – National Drug Treatment Monitoring System statistics 
showing that 42% of opioid service users across these 11 prisons have been released with THN, 28% 
higher than the national average of 12%.
The approach has also been welcomed by prison staff: 28%
higher than the 
national average of 
12%
“The Forward Trust provide an important service to HMP Lewes, offering a comprehensive package 
of support to the men here which is consistently well received (including, for example, the provision 
of naloxone take home kits). Feedback from the men who access their services is extremely positive. 
I am impressed with the level of professionalism the Forward Trust demonstrate across their team 
and their genuine desire to work collaboratively with HMP Lewes to support the men here to address 
their substance misuse issues. As part of the wider Reducing Reoffending group, they offer valuable 
contributions across all areas of the function. As a Head of Function, I have complete trust in their 
focus and approach” – Sally Charles, Head of Reducing Reoffending, HMP Lewes
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Mez, Blue Sky beneficiary
In addition to this statistical impact, which translates into many lives saved, our THN initiative has also had the impact of empowering 
service users to help others, exemplifying a fundamental aspect of Forward’s ethos, the importance of mutual aid and ‘giving back’:
Future development
Increasing THN take-up: Forward’s prison-based clinical services have made a strong start in increasing the uptake of THN 
amongst our service users in Kent, Surrey and Sussex. As our best practice process becomes fully embedded in every service, we 
expect the proportion of opioid service users released with naloxone to increase further. We have therefore set ourselves a target 
average rate of 50% of service users accepting THN on release across all the prisons where we provide clinical support.
Foreign nationals: Even though our service users at HMP Maidstone are not eligible to receive THN on release, we will continue 
to offer harm reduction information and advice throughout their treatment journey, in preparation for release. We will increase our 
portfolio of resources in different languages and support service users to access THN in their home country.
Rollout to other prison services: We plan to apply the learning from this initiative to other prison services where we offer 
psychosocial (non-clinical) substance misuse treatment only. Although THN is the responsibility of clinical providers, we can use 
our best practice to support our clinical partners and increase uptake of THN in all of the prisons we operate in.
Establishment No. of structured clients No. of opioid clients 
released
Proportion of opioid 
clients released with 
naloxone
High Down 23 234 23%
Downview 27 54 50%
Coldingley 1 4 25%
Send 16 22 73%
Lewes 69 144 48%
Elmley 124 226 55%
Swaleside 3 5 60%
Standford Hill 0 0 -
Rochester 26 64 41%
Maidstone** 0 7 0%
East Sutton Park 1 5 20%
All 320 765 42%
I used it to save my life
My friend came round [from the overdose]
(**Take-up is 0% at HMP Maidstone, as all service users are foreign nationals who are not eligible to receive THN on release.)
Forward's Take Home Naloxone figures for October 2018 – March 2019
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Find out more
To find out more about our programmes and research, contact Helen Greenard, Head of Research, Data and Performance: 
Helen.Greenard@forwardtrust.org.uk 
Training peer supporters: To enhance our provision of THN further, we will train our peer supporters to deliver naloxone training. 
Peer-led initiatives such as this can have numerous benefits,16 including:
• Reducing stigma around carrying naloxone
• Utilising the lived experiences of peers to break down barriers and motivate service users to change
• Challenging myths surrounding overdose
• Reaching those not in treatment
Nasal naloxone: Following the amendment to the Government’s guidance on widening the availability of naloxone, we will offer 
our service users the option of nasal naloxone.17 Not all service users (or their family and friends) are comfortable administering 
naloxone via intramuscular injection. Therefore, we expect that offering more than one method of administration will increase the 
uptake of THN in prisons and the community.
Community services: We will also apply the learning from our prison experience to our community substance misuse services. 
THN is offered to every opioid user, including those who were not offered it or declined it whilst in prison. Even though the 
likelihood of opioid overdose is higher following release from prison, all of our opioid service users in the community are offered 
THN and training. Unfortunately, only a small proportion of our opioid service users in the community accept THN. We plan to 
double this using the learning from our prison services and aforementioned initiatives.
11%
National average 
proportion of opioid 
clients receiving 
THN and training 
in community 
services
11%
Proportion of opioid 
clients receiving 
THN and training in 
Forward's East Kent 
community 
services
22%
Forward's target for 
uptake of THN in our 
community services by 
the end of the 2019-
2020 financial year
• New THN training programme for staff
• Re-offer THN throughout a service user’s treatment journey
• Training peer supporters to deliver THN training
• Provide the choice of nasal naloxone or intramuscular injection
How do we plan to increase uptake of THN amongst our community service users?
Pulse #7 7
References
1. Office for National Statistics. (2018). Deaths related to drug poisoning in England and Wales: 2017 registrations. 
https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/
deathsrelatedtodrugpoisoninginenglandandwales/2017registrations  
2. Ibid (see above reference)
3. National Crime Agency. (2017). Recent Deaths Possibly Linked to Fentanyl. http://www.nationalcrimeagency.gov.uk/
publications/795-recent-deaths-possibly-linked-to-fentanyl/file
4. Phillips, J., Gelsthorpe, L., & Padfield, N. (2017). Non-custodial deaths: Missing, ignored or unimportant? Criminology & Criminal 
Justice, https://doi.org/10.1177/1748895817745939
5. Bukten et al. (2017). High risk of overdose death following release from prison: variations in mortality during a 15-year 
observation period. Addiction, https://doi.org/10.1111/add.13803
6. Merrall, E. C., Kariminia, A., Binswanger, I. A., Hobbs, M. S., Farrell, M., Marsden, J. et al. (2010). Meta-analysis of drug-related deaths 
soon after release from prison. Addiction, https://doi.org/10.1111/j.1360-0443.2010.02990.x
7. Langham, S., Wright, A., Kenworthy, J., Grieve, R., & Dunlop, W. C. N. (2018). Cost-Effectiveness of Take-Home Naloxone for 
the Prevention of Overdose Fatalities among Heroin Users in the United Kingdom. Value in Health https://doi.org/10.1016/j.
jval.2017.07.014
8. Public Health England. (2017). Widening the availability of naloxone. https://www.gov.uk/government/publications/widening-the-
availability-of-naloxone/widening-the-availability-of-naloxone
9. Department of Health. (2017). Drug misuse and dependence: UK guidelines on clinical management. https://assets.publishing.
service.gov.uk/government/uploads/system/uploads/attachment_data/file/673978/clinical_guidelines_2017.pdf
10. Ibid (see above reference)
11. Public Health England. (2018). Fentanyl: Preparing for a future threat. https://www.gov.uk/government/publications/fentanyl-
preparing-for-a-future-threat
12. Bird, S. M., McAuley, A., Perry, S., & Hunter, C. (2016). Effectiveness of Scotland’s National Naloxone Programme for reducing 
opioid-related deaths: a before (2006-10) versus after (2011-13) comparison. Addiction, 111(5), 883-891.
13. Carre, Z. & Ali, A. (2019). Finding a Needle in a Haystack: Take-Home Naloxone in England 2017/18. London: Release.
14. Ibid (see above reference)
15. Ibid (see above reference)
16. Release. (2019). Naloxone Steering Group 2019. 1st April 2019, London, UK.
17. HM Government. (2019). Widening the availability of naloxone. https://www.gov.uk/government/publications/widening-the-
availability-of-naloxone/widening-the-availability-of-naloxone
Registered Charity No: 1001701
Registered Company No: 2560474
